French National Agency for Research on Aids and Viral Hepatitis

AIDS Vaccine 2009 - Scientific Program

Monday, 19 October 2009

08:00 - 16:00 Satellite Sessions

17:00 - 18:30 Welcome and Opening Remarks
Jean-François Delfraissy, ANRS, France
Alan Bernstein, Global HIV Vaccine Enterprise, USA
Michel Kazatchkine, The Global Fund to Fight AIDS, Tuberculosis and Maleria, Switerland
Michel Sidibé, UNAIDS, Switerland

17:40 - 18:05 The state of HIV prevention: How well are we doing in preventing HIV worldwide, and how can we do better?
Peter Piot, Global Health Institute, Imperial College, UK

18:05 - 18:30 Partner, participants and problem-solvers: Expanding from "Informed Consent" to "Informed Communities" in the Search for the AIDS Vaccine
Mitchell Warren, AVAC, USA

Tuesday, 20 October 2009

08:30 - 10:20 Special Session: Recent Lessons From Clinical Trials

08:30 - 09:00 AIDS Vaccine Clinical Evaluation: Where Are We and Where Can We Go?
Gary Nabel, Vacine Research Center, NIH, USA

09:00 - 09:20 Clinical Outcomes from the STEP Study
Susan Buchbinder, HIV Research Section, San Francisco Department of Public Health, USA

09:20 - 09:40 Recent Immunologic Findings from the Step and Related HIV Vaccine Clinical Trials
Nicole Frahm, Fred Hutchinson Cancer Research Center, USA

09:40 - 10:00 Interim Efficacy Analysis of HVTN 503/Phambili: A phase IIB test of concept trial of the MRKAd5 HIV-1 gag/pol/nef vaccine conducted in HIV-1 uninfected adults in South Africa
Glenda Gray, Perinatal HIV Research Unit, South Africa

10:00 - 10:20 Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Result of Final Analysis
Supachai Rerks-Ngarm, Ministry of Health, Thailand
11:00 - 12:30 Plenary Session 1: Initiation of the Immune Response

11:00 - 11:30 Innate Control of Adaptive Immunity to Vaccines and Pathogens
Bali Pulendran, Emory Vaccine Center, Emory University, USA

11:30 - 12:00 Harnessing Human Dendritic Cell Subsets for HIV Vaccines
Jacques Banchereau, Baylor Institute for Immunology Research, USA<

12:00 - 12:30 T cell control and viral escape
Phil Goulder, University of Oxford, UK

12:30 - 14:00 Lunch + Poster Session 01

14:00 - 16:00 Symposium 1: Mechanisms of Protection against Transmission and Disease Protection

14:00 - 14:25 Epigenetic control of retroelements
Didier Trono, École Polytechnique Fédérale de Lausanne, Switzerland

14:25 - 14:50 Crosstalk between RNAi and HIV
Monsef Benkirane, Institut de Génétique Humaine, France

14:50 - 15:15 Regulation of Harmful Immune Activation during Non Pathogenic SIVagm Infection in African Green Monkeys
Michaela Müller Trutwin, Institut Pasteur, France

15:15 - 15:30 Phenotypic Analyses of CD8+ T cells that Mediate Virus Inhibition from HIV-1 Vaccinees and HIV-1+ Virus Controllers
Stephanie Freel,Duke University Medical School, USA

15:30 - 15:45 HLA-A*7401 is Associated with Protection from HIV-1 Acquisition and Disease Progression in Mbeya, Tanzania
Rebecca Koehler,US Military HIV Research Program/ Henry M Jackson Foundation, USA

15:45 - 16:00 HIV Specific T Cell Responses and Response Patterns Associated with Viral Control Independent of Classical Non-Progessor HLA class I Alleles
Christian Brander, Irsicaixa AIDS Research Institute, Spain
14:00 - 16:00 Symposium 2: Generation of Antibody Responses and Diversity

14:00 - 14:25 Regulation of Broadly Neutralizing Antibody Responses: The Initial B Cell Repertoire To HIV-1 Envelope
Barton Haynes, Duke University Medical Center, USA

14:25 - 14:50 Factors Associated with the Development of HIV Neutralization Breadth
Lynn Morris, National Institute for Communicable Diseases, South Africa

14:50 - 15:15 Eliciting Broad Anti-HIV Neutralizing Antibodies by Vaccination: Lessons Learned from Natural Infection
Leonidas Stamatatos, Seattle Biomedical Research Institute, USA

15:15 - 15:30 A Large-Scale Analysis of Immunoglobulin Sequences Derived From Plasmablasts/Plasma Cells in Acute HIV-1 Infection Subjects
Supriya Munshaw, Duke University, USA

15:30 - 15:45 Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
Mikyung Kim,Dana-Farber Cancer Institute, USA

15:45 - 16:00 Potent and Broad Neutralizing Antibodies from HIV-1 non-Clade B Infected Donor Reveal a New HIV-1 Vaccine Target
Sanjay Phogat, IAVI, USA
16:00 - 17:00 Coffee Break + Poster Viewing

17:00 - 18:30 Oral Abstract Session 1: Early Events in Transmission and Infection

17:00 - 17:15 Early events of human immunodeficiency virus type 1 (HIV-1) ex vivo penetration in the foreskin mimicking HIV-1 sexual transmission
Yonatan Ganor, Cochin Institute, France

17:15 - 17:30 Defining the Mechanisms of HIV Entry and Interactions with the Female Genital Tract
Ann Carias, Northwestern University, USA

17:30 - 17:45 Clusterin, a natural ligand of DC-SIGN present in human semen inhibits HIV capture and transmission by dendritic cells
Juan Sabatte, National Reference Center for AIDS, Argentina

17:45 - 18:00 Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection.
Andrea Stacey,Jenner Institute, University of Oxford, UK

18:00 - 18:15 TLR-mediated pDC responses to HIV-1 ligands
J. Judy Chang, Ragon Institute of MGH, MIT and Harvard, USA

18:15 - 18:30 HIV-1 Plasma RNA Risk of HIV-1 Transmission
Jairam Lingappa, University of Washington, USA

17:00 - 18:30 Oral Abstract Session 2: Vaccine Design

17:00 - 17:15 Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
Bert Jacobs, Arizona State University, USA

17:15 - 17:30 Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
Frederic Tangy,Institut Pasteur, CNRS, France

17:30 - 17:45 Design and Development of DNA vaccines for the Co-expression of micro-RNA and HIV-1 Env
Adam Wheatley,University of Melbourne, Australia

17:45 - 18:00 HIV-1 gp41 Envelope MPER Mutation Altered Epitope Conformation in Lipid and Increased Sensitivity to 2F5 and 4E10 Neutralizing Antibodies
Xiaoying Shen, Duke University, USA

18:00 - 18:15 Insertion of the HIV-1 gp41 Epitopes 2F5 and 4E10 into the Membrane-Proximal Region of the Vesicular Stomatitis Virus Glycoprotein
Ivo Lorenz,International AIDS Vaccine Initiative, USA

18:15 - 18:30 Recombinant modified Vaccinia Virus Ankara expressing HIV-1 genes activates NK subset capable of controlling HIV infection in vitro
Jean-Saville Cummings, Institut Pasteur, France

17:00 - 18:30 Oral Abstract Session 3: Modulation of the Immune Response to Infection

17:00 - 17:15 HIV-1 infection is characterized by early loss of CD161+ Th17 Cells and Gradual Decline in Regulatory T cells
Andrew Prendergast,University of Oxford, UK

17:15 - 17:30 Regulatory T cells inhibit CD8 T cell proliferation in HIV-1 infection through CD39/Adenosine pathway
Yves Levy, AP-HP, Groupe Henri-Mondor Albert-Chenevier; Universite Paris 12, France

17:30 - 17:45 Increased Regulatory T cell Frequency and HIV-1 Specific Suppression After Therapeutic Vaccination of HIV-Infected Patients on Antiretroviral Therapy
Bernard Macatangay,University of Pittsburgh, USA

17:45 - 18:00 Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules
Hendrik Streeck, Ragon Institute of MGH, MIT and Harvard, USA

18:00 - 18:15 HIV escape from natural killer cytotoxicity: Nef inhibits NKp44L expression on HIV-infected CD4+ T cells.
Vincent Vieillard,INSERM UMR945, France

18:15 - 18:30 Unique stimulatory properties of myeloid dendrict cells in individuals with "elite" HIV-1 control
Mathias Lichterfeld, Massachusetts General Hospital, USA

Wednesday, 21 October 2009

09:00 – 10:30 Plenary Session 2: In Vivo Response to Pathogens and Vaccines

09:00 - 09:30 In Vivo Dynamics of the Immune Response as Revealed by Multiphoton Imaging
Ron Germain, NIAID NIH, USA

09:30 - 10:00 Efficacy of CMV/SIV Vectors
Louis Picker, Vaccine and Gene Therapy Insitute, OHSU, USA

10:00 - 10:30 TB Vaccine Development
Jerald Sadoff, AERAS Global TB Vaccine Foundation, USA

11:00 - 12:30 Oral Abstract Session 4: Update on Clinical Trials

11:00 - 11:15 Safety and Immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: Results of ANRS VAC18, a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Salmon-Céron, Hôpital Cochin, Université Paris Descartes, France

11:15 - 11:30 Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/ modified Vaccinia virus Ankara (MVA) heterologous boost vaccines
Charlotta Nilsson,Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden

11:30 - 11:45 Characterization of cell-mediated immune responses generated by recombinant Modified Vaccinia Ankara (rMVA)-HIV-1 in a Phase I Vaccine Trial
Jeffrey Currie, Military HIV Research Program, USA

11:45 - 12:00 Perceived parental willingness for their adolescents to participate in future HIV prevention trials: A survey conducted amongst adolescents in Soweto
Kennedy Otwombe,Perinatal HIV Research Unit, South Africa

12:00 - 12:15 Safety and Viral Load changes in HIV-1 Infected Subjects Treated with Autologous Dendritic Immune Therapy following ART discontinuation (CTN#239)
Jean-Pierre Routy,McGill University and INSERM Unit 743, Canada

12:15 - 12:30 Post-infection cellular immune responses in recipients following ALVAC-HIV + AISDVax B/E prime-boost vaccination in the Thai phase III trial
Jerome Kim, Military HIV Research Program, USA

11:00 - 12:30 Oral Abstract Session 5: Novel Vaccinal Approaches

11:00 - 11:15 In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
Sandhya Vasan, Aaron Diamond AIDS Research Center, Rockefeller University, USA

11:15 - 11:30 Analysis of DNA compared to Ad5 vaccination, as single and mixed modalities, demonstrates robust induction of cellular immune responses in macaques
Lauren Hirao,University of Pennsylvania, USA

11:30 - 11:45 Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques
Frédéric Martinon,CEA / Division of Immuno-Virology, France

11:45 - 12:00 Gp96-Ig-SIV vaccines induce predominant immune responses at mucosal sites
Natasa Strbo, University of Miami Miller School of Medicine, USA

12:00 - 12:15 Impact of in vivo CD4 binding during HIV-1 Env trimer immunizations of rhesus macaques
Iyadh Douagi, Karolinska Institutet, Sweden

12:15 - 12:30 First-in-human phase 1 saftey and immunogenicity of an Adenovirus Serotype 26 HIV-1 vaccine vector
Dan Barouch, Beth Israel Deaconess Medical Center, USA

11:00 - 12:30 Oral Abstract Session 6: Dynamics of HIV Infection and the Immune Response

11:00 - 11:15 Multiplicity of infection by HIV-1 in injection drug users, men who have sex with men and heterosexuals
Katharine Bar,University of Alabama at Birmingham, USA

11:15 - 11:30 Monospecific Expansion of SIVmac251 During Acute Infection Masks Multiple Transmitted Virus Variants Revealed During the Chronic Phase
Barbara Felber,HRPS, VB, NCI-Frederick, USA

11:30 - 11:45 Dynamics of CTL Epitope Escape and Reversion in an African Subtype C cohort
Malinda Schaefer,Emory University, USA

11:45 - 12:00 The Role Of Early T-Cell Responses In Subjects With Acute HIV-1 Infection
Michael Liu, University of Oxford, UK

12:00 - 12:15 Adaptation of HIV-1 to the Human Immune System at the Population Level is Driven by Protective HLA-B Alleles
Ingrid Schellens,University Medical Center Utrecht,Netherlands

12:15 - 12:30 Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
James Mullins, University of Washington, USA

12:30 - 14:00 Lunch + Poster Session 02

14:00 - 16:00 Symposium 3: Immunological Memory and Protection

14:00 - 14:25 System Biology to Study Immunological Memory during HIV Infection
Elias Haddad, McGill University, Canada

14:25 - 14:50 Correlates of protection to HIV
Alexandre Harari, Centre Hospitalier Universitaire Vaudois, Switzerland

14:50 - 15:15 T Cell Clonotypic Correlates of Virus Control
Daniel Douek, Vaccine Research Center, NIH, USA

15:15 - 15:30 Transitional and Central Memory CD4 T Cells are highly infected in Long Term Non Progressors and Elite Controllers
Benjamin Descours, Université Paris VI UPMC, INSERM UMRs945, France

15:30 - 15:45 A Less Differentiated Memory Phenotype of Gag-Specific CD4+ T-cells during Primary HIV Infection Associates with Viral Control at 12 Months
Pholo Maenetje, National Institutes for Communicable Diseases, South Africa

15:45 - 16:00 Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication
Adam Hersperger, University of Pennsylvania, USA

14:00 - 16:00 Symposium 4: Antigen Presentation and T Cell Epitopes

14:00 - 14:25 Semen clusterin binds DC-SIGN and inhibits HIV-1 capture and transmission by dendritic cells
Sebastian Amigorena, Institut Curie, Paris, France

14:25 - 14:50 Immune recognition of HIV-1 during acute infection
Marcus Altfeld, Ragon Institute of MGH, MIT and Harvard, USA

14:50 - 15:15 Transcriptional control of crosspresentation programs in dendritic cells
Kenneth Murphy, Washington University School of Medicine, USA

15:15 - 15:30 HIV-specific responses induced by anti-CD40 targeting antibodies
Nicolas Loof,INSERM U899-BIIR/INSERM/ANRS Center for Human Vaccines, USA

15:30 - 15:45 The intracellular production of HIV antigenic peptides is guided by predictable motifs and can be altered: implications for immunogen design
Sylvie Le Gall,Harvard Medical School and Mass General Hospital, USA

15:45 - 16:00 Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads
Boris Julg, Ragon Institute of MGH, MIT and Harvard, USA

16:00 - 17:00 Coffee Break + Poster Viewing
17:00 - 18:40 Symposium 5: Protection Against Mucosal Transmission and Viral Dissemination

17:00 - 17:25 Characterization of viral variants that initiate systemic infection after mucosal transmission
Eric Hunter, Emory Vaccine Center, USA

17:25 - 17:50 Target Cell Availability and Prevention of Mucosal Transmission
Ashley Haase, University of Minnesota Medical School, USA

17:50 - 18:15 Do Mucosal T-cell Responses Contribute Significantly to HIV Control?
Barbara Shacklett, UC Davis, USA

18:15 - 18:40 Treatment as Prevention
Bernard Hirschel, University Hospital Geneva, Switzerland

17:00 - 18:40 Symposium 6: Refining Immunogen Design

17:00 - 17:25 Structural basis of broad neutralization of HIV-1
Ian Wilson, The Scripps Research Institute, USA

17:25 - 17:50 Primary Immunization Influences the Magnitude, Quality and Breadth of Gag Specific T Cell Responses Following an rAd-5 Boost
Robert Seder, Vaccine Research Center, NIH, USA

17:50 - 18:15 New Applications for Mosaic Antigen Designs
Bette Korber, Los Alamos National Laboratory, USA

18:15 - 18:40 HIV-1 Mosaic Antigens Expand Cellular Immune Breadth and Depth in Rhesus Monkeys
Dan Barouch, Beth Israel Deaconess Medical Centre, Harvard Medical School, USA

Thursday, 22 October 2009

09:00 – 10:30 Plenary Session 3: B Cell Biology

09:00 – 09:30 Development of anti-HIV antibodies in humans with high titers of broadly neutralizing antibodies
Michel Nussenzweig, Howard Hughes Medical Institute, The Rockefeller University, USA

09:30 – 10:00 From Antibody to Vaccine – a Tale of Structural Biology and Epitope Scaffolds
Peter Kwong, Vaccine Research Center, NIH, USA

10:00 - 10:30 Induction and Function of the Mucosal Immune System
Per Brandtzaeg, University of Oslo, Norway

11:00 - 12:00 Oral Abstract Session 7: T Cell Responses to Vaccine

11:00 - 11:15 HIV-Specific CD8+ T-Cells of Vaccinees Exhibit Proliferative and Cytotoxic Capacities Comparable to Those of Progressors
Julia Rood, National Institute of Health, USA

11:15 - 11:30 Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection.
Adel Benlahrech, Imperial College, UK

11:30 - 11:45 Influence of Preexisting Vaccinia Immunity on a DNA/MVA SIV Vaccine, Decreased Cellular Immunity but Enhanced Control of a Pathogenic SIV Challenge
Rama Amara, Yerkes National Primate Center of Emory University, USA

11:45 - 12:00 Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boost vaccination in RV144, the Thai phase III HIV vaccine trial
Mark de Souza, US Military HIV Research Program/AFRIMS, Thailand

12:00 - 12:50 Closing Session

12:00 - 12:25 HIV Vaccinology: What Does the Future Hold?
Anthony Fauci, NIAID, NIH, USA

12:25 - 12:50 Are we targeting the right HIV determinants?
Françoise Barré-Sinoussi, Institut Pasteur, France

12:50 - 13:00 Closing Remarks and Handover

12:50 - 12:55 Yves Levy, ANRS, France
12:55 - 13:00 Eric Hunter, Emory Vaccine Center, USA

© 2005 - 2009 Global HIV Vaccine Enterprise